Drugs / Adebelizumab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07004712 | Jun 2025 → Mar 2028 expected | small cell lung carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06125041 | Oct 2023 → Jul 2026 overdue | small cell lung carcinoma | Qianfoshan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05769010 | Mar 2023 → Dec 2028 expected | breast cancer | Henan Cancer Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adebelizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06125041 ↗ |
| Route | Intravenous | “adebelizumab (20mg/kg, IV, Q3W)” NCT06125041 ↗ |